These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10028949)

  • 1. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.
    Maschio G; Alberti D; Locatelli F; Mann JF; Motolese M; Ponticelli C; Ritz E; Janin G; Zucchelli P
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S16-20; discussion S41-3. PubMed ID: 10028949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Maschio G; Alberti D; Janin G; Locatelli F; Mann JF; Motolese M; Ponticelli C; Ritz E; Zucchelli P
    N Engl J Med; 1996 Apr; 334(15):939-45. PubMed ID: 8596594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of benazepril for advanced chronic renal insufficiency.
    Hou FF; Zhang X; Zhang GH; Xie D; Chen PY; Zhang WR; Jiang JP; Liang M; Wang GB; Liu ZR; Geng RW
    N Engl J Med; 2006 Jan; 354(2):131-40. PubMed ID: 16407508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
    Zhang GH; Hou FF; Zhang X; Liu QF
    Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
    Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Locatelli F; Carbarns IR; Maschio G; Mann JF; Ponticelli C; Ritz E; Alberti D; Motolese M; Janin G; Zucchelli P
    Kidney Int Suppl; 1997 Dec; 63():S63-6. PubMed ID: 9407424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.
    Rose GW; Kanno Y; Ikebukuro H; Kaneko M; Kaneko K; Kanno T; Ishida Y; Suzuki H
    Hypertens Res; 2001 Jul; 24(4):377-83. PubMed ID: 11510750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease.
    Ishimitsu T; Akashiba A; Kameda T; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
    Nephrology (Carlton); 2007 Jun; 12(3):294-8. PubMed ID: 17498126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J; Kanno Y; Suzuki H
    Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
    Suzuki H; Kanno Y; Ikeda N; Nakamoto H; Okada H; Sugahara S
    Hypertens Res; 2002 Nov; 25(6):865-73. PubMed ID: 12484510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
    Coppo R; Peruzzi L; Amore A; Piccoli A; Cochat P; Stone R; Kirschstein M; Linné T
    J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
    Hogan TJ; Elliott WJ; Seto AH; Bakris GL
    Pharmacoeconomics; 2002; 20(1):37-47. PubMed ID: 11817991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of benazepril in essential hypertension.
    MacNab M; Mallows S
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV33-7; discussion IV51-5. PubMed ID: 1893640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.